ZEDRON 8MG TABLET

Overview

ZEDRON is oral and parenteral antiemetic agent. ZEDRON is the first selective serotonin blocking agent to be marketed. Ondansetron (HCL) his extremely safe and highly effective antiemetic that has greatly improved the ability to give chemotherapy. The quality of life of patients has been tremendously better with ondansetron than with older, traditional antiemetics. Despite its effectiveness ondansetron is not recommended for the routine treatment of nausea due to its significant cost. Ondansetron was originally approved for the treatment of chemotherapy-induced nausea/vomiting by the FDA in January 1991 and tablets were approved for the treatment of post-operative nausea/vomiting in April 1995. It may have central and/or peripheral action, selectively blocks the serotonin 5-HT1 receptors. 5-HT1receptors are found centrally in the chemoreceptor trigger zone and peripherally at vagal nerve terminals in the intestines

Indications

ZEDRON is primarily indicated in conditions like Moderately emetognic chemotherapy or radiotherapy, Nausea and vomiting (chemotherapy induced). Post operative vomiting, Post-operative nausea, Post-operative nausea and vomiting. Prevention of post-operative nausea and vomiting, Severely emetognic chemotherapy

Contraindication

Ondansetron (HC) is contraindicated in conditions like Hypersensitivity

Side Effects

The severe or irreversible adverse effects of ZEDRON, which give rise to further complications include Cardiac arrhythmias, Bronchospasm, Cardiac arrhythmias, Bradycardia, Bronchospasm, Angioedema, Angina, Angioedema, Hyperbilirubinemia. The symptomatic adverse reactions produced by ZEDRON are more or less tolerable and if they become severe they can be treated symptomatically, these include Dizziness, Headache, Fever, Dyspnea, Constipation, Abdominal pain, Chills, Hypotension, Flushing, Hiccups, Xerostomia, Vision disturbances, Reaction at injection site, Warmth sensation, dizziness, Hypotension

Warnings

Dosage restriction is advisable in patients with moderate to severe liver impairment. Ondansetron should be used with caution during pregnancy or lactation. Care is required in the patient exhibiting hypersensitivity to other selective 5HT3 receptor antagonists and in patient with signs of subacute intestinal obstruction

High Risk Groups

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies